Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold

Maximilian Koch, Johannes S de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E Lamberts, Arthur L. L. Adams, Mariëtte E G Kranendonk, Anton G T Terwisscha van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D Linssen, Esther de Boer, Bert van der Vegt, Wouter B Nagengast, Sjoerd G Elias, Sabrina OliveiraArjen J. Witkamp, Willem P Th M Mali, Elsken van der Wall, Beatriz P Garcia-Allende, Paul J van Diest, Elisabeth G de Vries, Axel Walch, Gooitzen M van Dam, Vasilis Ntziachristos

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold'. Together they form a unique fingerprint.

Keyphrases

Immunology and Microbiology